Beta Bionics, Inc. (BBNX)
NASDAQ: BBNX · Real-Time Price · USD
10.61
-0.50 (-4.50%)
At close: Mar 6, 2026, 4:00 PM EST
10.50
-0.11 (-1.04%)
After-hours: Mar 6, 2026, 7:58 PM EST

Beta Bionics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
Revenue
100.2565.12120.18
Revenue Growth (YoY)
53.94%442.93%6601.12%-
Cost of Revenue
44.7129.245.69-
Gross Profit
55.5435.896.310.18
Selling, General & Admin
92.4354.9624.2233.5
Research & Development
34.7926.1817.9431.43
Operating Expenses
127.2281.1442.1664.92
Operating Income
-71.68-45.25-35.85-64.74
Interest Expense
----0.01
Interest & Investment Income
10.933.911.780.2
Other Non Operating Income (Expenses)
-12.45-13.41-10.030.91
EBT Excluding Unusual Items
-73.2-54.76-44.1-63.65
Other Unusual Items
----1.1
Pretax Income
-73.2-54.76-44.1-64.75
Net Income
-73.2-54.76-44.1-64.75
Net Income to Common
-73.2-54.76-44.1-64.75
Shares Outstanding (Basic)
41655
Shares Outstanding (Diluted)
41655
Shares Change (YoY)
536.74%20.01%6.13%-
EPS (Basic)
-1.81-8.60-8.31-12.96
EPS (Diluted)
-1.81-8.60-8.31-12.96
Free Cash Flow
-56.22-51.67-32.85-60.98
Free Cash Flow Per Share
-1.39-8.12-6.19-12.20
Gross Margin
55.40%55.11%52.59%100.00%
Operating Margin
-71.50%-69.48%-298.88%-36169.83%
Profit Margin
-73.02%-84.08%-367.64%-36173.74%
Free Cash Flow Margin
-56.08%-79.34%-273.84%-34067.04%
EBITDA
-70.11-44.1-34.62-63.4
EBITDA Margin
-69.93%-67.72%-288.65%-
D&A For EBITDA
1.571.151.231.35
EBIT
-71.68-45.25-35.85-64.74
EBIT Margin
-71.50%-69.48%-298.87%-
Revenue as Reported
---0.18
Source: S&P Capital IQ. Standard template. Financial Sources.